Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-8800
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
2024 年 3 月期 · Second quarter (cumulative) / Full yearPrevious forecast published 2023 年 5 月 11 日Net Sales2Q cumulative33,600→27,400million
-18.5%
Net SalesFull year69,300→60,500million
-12.7%
Operating profit2Q cumulative7,100→5,500million
-22.5%
Operating profitFull year13,800→10,950million
-20.7%
Ordinary income2Q cumulative7,100→6,050million
-14.8%
Ordinary incomeFull year13,800→11,550million
-16.3%
Profit attributable to owners of the parent2Q cumulative4,850→4,100million
-15.5%
Profit attributable to owners of the parentFull year9,450→7,900million
-16.4%
Net income per share2Q cumulative137.61→116.32yen and sen
-15.5%
Net income per shareFull year268.13→224.13yen and sen
-16.4%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
ライフサイエンス事業では工業用途の需要落ち込みが長期化し、中国市場・欧州経済の低迷、コロナ禍の物流混乱による世界的な在庫増加の反動もあって売上高が計画を下回る見込みとなった。電子材料および機能性化学品事業では半導体市場の低迷が長期化し、超高純度コロイダルシリカの売上高が計画を大きく下回る見込みとなった。売上減少、原料価格・輸入価格の上昇、稼働率低下によるコストアップの影響が、円安による効果や為替差益を上回る見込みとしている。
Previous-period results2Q cumulative Fiscal Year-End 2023 年 3 月期第 2 四半期 / Net Sales 35,359 百万円（1株当たり四半期純利益は円 銭） / Operating profit 9,578 百万円（1株当たり四半期純利益は円 銭） / Ordinary income 10,757 百万円（1株当たり四半期純利益は円 銭） / Profit attributable to owners of parent for the quarter 7,516 百万円（1株当たり四半期純利益は円 銭） / Quarterly earnings per share 213.26 百万円（1株当たり四半期純利益は円 銭） / Full year Fiscal Year-End 2023 年 3 月期 / Net Sales ¥68,459 million (net income per share: yen and sen) / Operating profit ¥18,930 million (net income per share: yen and sen) / Ordinary income ¥19,740 million (net income per share: yen and sen) / Profit attributable to owners of the parent ¥14,129 million (net income per share: yen and sen) / Earnings per share ¥400.9 million (net income per share: yen and sen)
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | 2Q cumulative 33,600 / Full year 69,300 → 2Q cumulative 27,400 / Full year 60,500（2Q cumulative -18.5 / Full year -12.7） |
| Operating profit | 2Q cumulative 7,100 / Full year 13,800 → 2Q cumulative 5,500 / Full year 10,950（2Q cumulative -22.5 / Full year -20.7） |
| Ordinary income | 2Q cumulative 7,100 / Full year 13,800 → 2Q cumulative 6,050 / Full year 11,550（2Q cumulative -14.8 / Full year -16.3） |
| Profit attributable to owners of the parent | 2Q cumulative 4,850 / Full year 9,450 → 2Q cumulative 4,100 / Full year 7,900（2Q cumulative -15.5 / Full year -16.4） |
| Net income per share | 2Q cumulative 137.61 / Full year 268.13 → 2Q cumulative 116.32 / Full year 224.13 |
| Fiscal Period Covered | 2024 年 3 月期 |
| Period Covered | Second quarter (cumulative) / Full year |
| Publication date of previous forecast | 2023 年 5 月 11 日 |
| Previous-period results | 2Q cumulative Fiscal Year-End 2023 年 3 月期第 2 四半期 / Net Sales 35,359 百万円（1株当たり四半期純利益は円 銭） / Operating profit 9,578 百万円（1株当たり四半期純利益は円 銭） / Ordinary income 10,757 百万円（1株当たり四半期純利益は円 銭） / Profit attributable to owners of parent for the quarter 7,516 百万円（1株当たり四半期純利益は円 銭） / Quarterly earnings per share 213.26 百万円（1株当たり四半期純利益は円 銭） / Full year Fiscal Year-End 2023 年 3 月期 / Net Sales ¥68,459 million (net income per share: yen and sen) / Operating profit ¥18,930 million (net income per share: yen and sen) / Ordinary income ¥19,740 million (net income per share: yen and sen) / Profit attributable to owners of the parent ¥14,129 million (net income per share: yen and sen) / Earnings per share ¥400.9 million (net income per share: yen and sen) |
| Reason for the revision | ライフサイエンス事業では工業用途の需要落ち込みが長期化し、中国市場・欧州経済の低迷、コロナ禍の物流混乱による世界的な在庫増加の反動もあって売上高が計画を下回る見込みとなった。電子材料および機能性化学品事業では半導体市場の低迷が長期化し、超高純度コロイダルシリカの売上高が計画を大きく下回る見込みとなった。売上減少、原料価格・輸入価格の上昇、稼働率低下によるコストアップの影響が、円安による効果や為替差益を上回る見込みとしている。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ライフサイエンス事業では工業用途、中国・欧州を中心とする海外需要の低迷や在庫増加の反動により売上高が計画を下回る見込みとなった。電子材料および機能性化学品事業では、半導体市場の低迷により主力製品の売上高が計画を大きく下回り、稼働率低下によるコストアップも利益を押し下げる見込みとなった。円安による売上高・為替差益の効果はあるものの、売上減少、原料価格や輸入価格の上昇の影響が大きいとしている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.